Research programme: antibacterial therapeutics - Enbiotix

Drug Profile

Research programme: antibacterial therapeutics - Enbiotix

Alternative Names: EBX 001; EBX 002; EPP 001

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator EnBiotix
  • Class Aminoglycosides; Antibacterials
  • Mechanism of Action Bacteria replacements; Bacterial growth modulators; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Pseudomonal infections; Urinary tract infections

Most Recent Events

  • 13 Jun 2016 EnBiotix enters a co-development agreement with Mayo Clinic for the development of EPP 001
  • 24 May 2016 EnBiotix plans a phase I/IIa trial for Urinary tract infections and Pseudomonal infections in USA (EnBiotix corporate presentation, May 2016)
  • 12 May 2016 Preclinical trials in Urinary tract infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top